- Teva’s 2Q revenue was $4.16 billion, higher than the estimated $4.05 billion.
- Revenue from Austedo in North America reached $407 million.
- Treanda & Bendeka generated $41 million in North America revenue.
- Copaxone’s revenue breakdown:
- North America: $81 million
- Europe: $53 million
- International: $14 million
- Adjusted EPS was 61 cents.
- Adjusted EBITDA stood at $1.17 billion, exceeding the estimated $1.14 billion.
- Teva’s total debt is $18.64 billion.
- Analyst ratings:
- 8 buys
- 2 holds
- 1 sell
A look at Teva Pharmaceutical Industries Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Teva Pharmaceutical Industries seems to have a promising long-term outlook. The company received high scores in Growth and Momentum, indicating strong potential for future expansion and positive market performance. These factors suggest that Teva Pharmaceutical Industries is well-positioned to capitalize on growth opportunities and maintain a positive trajectory in the pharmaceutical industry.
Although the company scored lower in Value, Dividend, and Resilience, the high scores in Growth and Momentum outweigh these lower scores. Teva Pharmaceutical Industries operates as a pharmaceutical company, developing, manufacturing, and marketing generic and branded human pharmaceuticals. With a global customer base, the company has the potential to build on its strengths in Growth and Momentum to drive long-term success and value creation.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
